Skip to main content
Lillian Guenther, MD
Lillian Macrae Guenther, MD

Lillian Macrae Guenther, MD

Assistant Member, St. Jude Faculty




  • Clinical/Postdoctoral Fellowship  (Pediatric Hematology/Oncology) - Dana-Farber Cancer Institute and Boston Children’s Hospital, Boston, MA
  • Internship and Residency (General Pediatrics) - Boston Combined Residency Program (Boston Children’s Hospital/Boston Medical Center), Boston, MA
  • MD – SUNY Downstate Medical Center, Brooklyn, NY
  • BA (History) – Brown University, Providence, RI

Honors and Awards

  • 2022 Children’s Cancer Research Fund Emerging Scientist Award
  • 2022 SARC Career Development Award
  • 2019 Rally Foundation Independent Investigator Award
  • 2018 – 2022 Damon Runyon Cancer Research Foundation Physician-Scientist Training Award
  • 2018 – 2020 Boston Children’s Hospital Office of Faculty Development Career Development Award
  • 2018 – 2019 QuadW Foundation/AACR Fellowship for Clinical/Translational Sarcoma Research
  • 2018 Scholar-in-Training Award, American Association for Cancer Research (AACR) Annual Meeting
  • 2017 – 2022 NIH/NCI Pediatric Research Loan Repayment Program
  • 2008 – 2009 Howard Hughes Medical Institute/National Institutes of Health (NIH) Research Scholar

Research Interests

  • Biologic investigation of novel dependency genes in pediatric osteosarcoma
  • DNA damage repair mechanisms in pediatric osteosarcoma
  • Development of novel therapeutic strategies for pediatric bone sarcomas
  • Applications of genomic and chemical screening to identify targeted combinations in pediatric bone sarcomas

Selected Publications

Tokarsky EJ, Crow JC, Guenther LM, Sherman J, Taslim C, Alexe G, Pishas KI, Rask G, Justis BS, Kasumova A, Stegmaier K, Lessnick SL, Theisen ER. Mitochondrial Dysfunction Is a Driver of SP-2509 Drug Resistance in Ewing Sarcoma. Mol Cancer Res Jul 6;20(7):1035-1046, 2022. PMID: 35298000

Dharia NV, Kugener G, Guenther LM, Malone CF, Durbin AD, Hong AL, Howard TP, Bandopadhayay P, Wechsler CS, Fung I, Warren AC, Dempster JM, Krill-Burger JM, Paolella BR, Moh P, Jha N, Tang A, Montgomery P, Boehm JS, Hahn WC, Roberts CWM, McFarland JM, Tsherniak A, Golub TR, Vazquez F, Stegmaier K. A First-Generation Pediatric Cancer Dependency Map. Nat Genet Apr; 53(4):529-538, 2021. PMID: 33753930

Chen S, Guenther LM, Aronhalt A, Cardillo L, Janeway KA, Church A. PD-1 and PD-L1 Expression 5 in Osteosarcoma: Which Specimen to Evaluate? J Pediatr Hematol Oncol Nov; 42(8):482-487, 2020. PMID: 31842180

Guenther LM, Dharia NV, Ross L, Conway A, Robichaud AL, Catlett JL 2nd, Wechsler CS, Frank ES, Goodale A, Church AJ, Tseng YY, Guha R, McKnight CG, Janeway KA, Boehm JS, Mora J, Davis MI, Alexe G, Piccioni F, Stegmaier K. A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing sarcoma. Clin Cancer Res Feb 15;25(4):1343-1357, 2019. PMID: 30397176

Guenther LM, Rowe RG, Acharya PT, Swenson DW, Meyer SC, Clinton CM, Guo D, Sridharan M, London WB, Grier HE, Ecklund K, Janeway KA. Response Evaluation Criteria in Solid Tumors (RECIST) Following Neoadjuvant Chemotherapy in Osteosarcoma. Pediatr Blood Cancer Apr;65(4):1-6, 2018, PMID: 29251406

Wan X, Kim SY, Guenther LM, Mendoza A, Briggs J, Yeung C, Currier D, Zhang H, Li WJ, Tuan RS, Deyrup AT, Khanna C, Helman L. Beta4 integrin promotes osteosarcoma metastasis and interacts with ezrin. Oncogene 28(38):3401-11, 2009. PMID: 19597468

Last update: October 2022